V.M.J. Novotný

1.5k total citations
28 papers, 1.1k citations indexed

About

V.M.J. Novotný is a scholar working on Hematology, Biochemistry and Physiology. According to data from OpenAlex, V.M.J. Novotný has authored 28 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 11 papers in Biochemistry and 9 papers in Physiology. Recurrent topics in V.M.J. Novotný's work include Blood groups and transfusion (14 papers), Blood transfusion and management (11 papers) and Erythrocyte Function and Pathophysiology (9 papers). V.M.J. Novotný is often cited by papers focused on Blood groups and transfusion (14 papers), Blood transfusion and management (11 papers) and Erythrocyte Function and Pathophysiology (9 papers). V.M.J. Novotný collaborates with scholars based in Netherlands, Germany and South Africa. V.M.J. Novotný's co-authors include G.J.C.G.M. Bosman, F.L.A. Willekens, J. M. Werre, Edwin Lasonder, Marleen Luten, Harry Bos, Bregt Roerdinkholder‐Stoelwinder, Willem J. de Grip, Anneke Brand and Yvonne A. M. Groenen‐Döpp and has published in prestigious journals such as Nature Communications, PLoS ONE and The Journal of Infectious Diseases.

In The Last Decade

V.M.J. Novotný

24 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
V.M.J. Novotný Netherlands 16 550 419 333 294 193 28 1.1k
Marleen Luten Netherlands 9 499 0.9× 295 0.7× 331 1.0× 244 0.8× 161 0.8× 12 891
Harry Bos Netherlands 7 454 0.8× 197 0.5× 186 0.6× 221 0.8× 134 0.7× 9 647
I. O. Szymanski United States 17 270 0.5× 273 0.7× 153 0.5× 54 0.2× 73 0.4× 39 666
Egarit Noulsri Thailand 13 178 0.3× 203 0.5× 30 0.1× 47 0.2× 216 1.1× 50 695
Photis Beris Switzerland 16 115 0.2× 466 1.1× 110 0.3× 35 0.1× 137 0.7× 44 796
Sip Dinkla Netherlands 9 202 0.4× 112 0.3× 38 0.1× 116 0.4× 163 0.8× 12 460
Meghna Alimchandani United States 14 73 0.1× 68 0.2× 115 0.3× 62 0.2× 79 0.4× 22 629
Patricia O. Skacel United Kingdom 12 52 0.1× 150 0.4× 184 0.6× 26 0.1× 103 0.5× 18 550
Lawrence N. Button United States 10 74 0.1× 118 0.3× 75 0.2× 96 0.3× 99 0.5× 14 621
Ronald Bukowski United States 10 45 0.1× 481 1.1× 112 0.3× 98 0.3× 133 0.7× 23 999

Countries citing papers authored by V.M.J. Novotný

Since Specialization
Citations

This map shows the geographic impact of V.M.J. Novotný's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V.M.J. Novotný with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V.M.J. Novotný more than expected).

Fields of papers citing papers by V.M.J. Novotný

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V.M.J. Novotný. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V.M.J. Novotný. The network helps show where V.M.J. Novotný may publish in the future.

Co-authorship network of co-authors of V.M.J. Novotný

This figure shows the co-authorship network connecting the top 25 collaborators of V.M.J. Novotný. A scholar is included among the top collaborators of V.M.J. Novotný based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V.M.J. Novotný. V.M.J. Novotný is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Nijhof, Inger S., Abraham Goorhuis, Arnon P. Kater, et al.. (2022). Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial. The Journal of Infectious Diseases. 227(2). 206–210. 16 indexed citations
3.
4.
Slot, Ed, Boris M. Hogema, Chantal Reusken, et al.. (2020). Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands. Nature Communications. 11(1). 5744–5744. 57 indexed citations
5.
Queckenberg, Christian, et al.. (2015). Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations. Cancer Chemotherapy and Pharmacology. 76(5). 1081–1091. 14 indexed citations
6.
Bosman, G.J.C.G.M., et al.. (2010). Susceptibility to hyperosmotic stress–induced phosphatidylserine exposure increases during red blood cell storage. Transfusion. 51(5). 1072–1078. 57 indexed citations
7.
Bosman, G.J.C.G.M., Edwin Lasonder, Yvonne A. M. Groenen‐Döpp, et al.. (2009). Comparative proteomics of erythrocyte aging in vivo and in vitro. Journal of Proteomics. 73(3). 396–402. 89 indexed citations
8.
Semmekrot, B. A., V.M.J. Novotný, Leendert Porcelijn, et al.. (2008). Fetal/Neonatal Allo-Immune Thrombocytopenia (FNAIT): Past, Present, and Future. Obstetrical & Gynecological Survey. 63(4). 239–252. 20 indexed citations
9.
Bosman, G.J.C.G.M., Edwin Lasonder, Marleen Luten, et al.. (2008). The proteome of red cell membranes and vesicles during storage in blood bank conditions. Transfusion. 48(5). 827–835. 177 indexed citations
10.
Bosman, G.J.C.G.M., Edwin Lasonder, Marleen Luten, et al.. (2008). The proteome of red cell membranes and vesicles during storage in blood bank conditions. Transfusion. 48(5). 827–835. 140 indexed citations
11.
Novotný, V.M.J.. (2007). Red cell transfusion in medicine: Future challenges. Transfusion Clinique et Biologique. 14(6). 538–541. 6 indexed citations
12.
Brand, Anneke, et al.. (2006). Platelet Transfusion Therapy: From 1973 to 2005. Human Immunology. 67(6). 413–418. 10 indexed citations
13.
Novotný, V.M.J., Ilias I.N. Doxiadis, & Anneke Brand. (1999). The reduction of HLA class I expression on platelets: A potential approach in the management of HLA-alloimmunized refractory patients. Transfusion Medicine Reviews. 13(2). 95–105. 16 indexed citations
14.
Novotný, V.M.J.. (1999). Prevention and Management of Platelet Transfusion Refractoriness. Vox Sanguinis. 76(1). 1–13. 61 indexed citations
15.
Novotný, V.M.J.. (1999). Prevention and Management of Platelet Transfusion Refractoriness. Vox Sanguinis. 76(1). 1–13. 64 indexed citations
16.
Novotný, V.M.J., Ilias I.N. Doxiadis, R van Doorn, & Anneke Brand. (1996). The kinetics of HLA class I elution and the relevance for the use of HLA‐eluted platelet transfusions. British Journal of Haematology. 95(2). 416–422. 16 indexed citations
17.
Novotný, V.M.J., T. Huizinga, R van Doorn, E Briët, & Anneke Brand. (1996). HLA class I‐eluted platelets as an alternative to HLA‐matched platelets. Transfusion. 36(5). 438–444. 22 indexed citations
18.
Novotný, V.M.J.. (1995). Platelet transfusion refractoriness — Prevention and therapeutical approaches. Transfusion Clinique et Biologique. 2(1). 47–49. 1 indexed citations
19.
20.
Novotný, V.M.J., et al.. (1992). Transfusion Results of Filtered and Subsequently Stored Random Platelet Suspensions Prepared from Buffy Coats. Vox Sanguinis. 63(1). 23–30. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marleen Luten Breakdown of academic impact, for papers by Harry Bos Breakdown of academic impact, for papers by I. O. Szymanski Breakdown of academic impact, for papers by Egarit Noulsri Breakdown of academic impact, for papers by Photis Beris Breakdown of academic impact, for papers by Sip Dinkla Breakdown of academic impact, for papers by Meghna Alimchandani Breakdown of academic impact, for papers by Patricia O. Skacel Breakdown of academic impact, for papers by Lawrence N. Button Breakdown of academic impact, for papers by Ronald Bukowski
Rankless by CCL
2026